About US

CEO Message Heartseed Inc. CEO
                  Keiichi FUKUDA, MD/ PhD/FACC

CEO Message

Since its establishment in 2015, Heartseed has been conducting its research and development to realize cardiac regenerative therapy as soon as possible, with the mission of “Open the door for cardiovascular disease treatment with regenerative medicine”

Heart failure is a disease caused by necrosis of heart tissue due to a myocardial infarction and the like, resulting in a decrease in heart pump function. The number of patients is 1.3 million in Japan and 5 million in the United States. Heart tissue that has been lost cannot be recovered, and only heart transplantation has the potential for cure. However, the reality is that there is a shortage of heart donors and sufficient treatment has not been delivered.

For that heart failure, we are developing a therapeutic method to generate cardiomyocytes from iPS cells and transplant them into cardiac tissue. Since I first reported in the world that cardiomyocytes can be generated from bone marrow stromal cells in 1995, many clinical studies have been conducted to administer mesenchymal cells, but all have achieved insufficient effects. From then back on, based on the idea that the only way to treat heart failure effectively is to make and transplant a large number of cardiomyocytes, always keeping in mind the safety and merits of patients and the industrialization of regenerative medicine, we have been conducting research on cardiac regenerative medicine using ES and iPS cells.

With the support and cooperation of numerous companies, academia and the Japanese government, we are nearing the start of clinical trials of our lead pipeline, HS-001. In addition, in order to make cardiac regenerative medicine easily available in the world, we are also conducting research on next-generation pipelines and production of iPS cell effectively and efficiently. With the realization of true regenerative medicine in the field of cardiovascular disease, we will work together to make a better world and become a leading company in regenerative medicine. We look forward to your continued guidance and support.

Heartseed Inc. CEO
Keiichi FUKUDA, MD/ PhD/FACC

Origin of our company name, Heartseed
Company nameの由来

cardiomyocyte spheroid, a spherical microtissue of cardiomyocytes which we create, resembles a species of houseplant called Heartseed. Named with the meaning of implanting a heart species at necrotic site due to myocardial infarction etc.

Mission & Value

Mission
Open the door of CV disease treatment with RM
Change the world with RM
Value
Provide Patient-first, high-quality care
Create a new medical care with original technology and science
Heart failure is difficult to cure. It is our mission to cure those patients with cardiac regenerative medicine. Many patients are waiting in the world. We aim to change the world by regenerative medicine.

Company Profile

Company name
Heartseed Inc.
Business
Cardiac regenerative medicine using iPSCs
Board member
Keiichi Fukuda, Kikuo Yasui, Takumi Akiyama
Outside Director
Yutaro Kasai, Toshiharu Furukawa
Shareholders
Founders/employees, Angel Bridge, Astellas Venture Management, Shibuya Corp., SBI Investment, JMDC, Gene Techno Science, Nissay Capital, SMBC Venture Capital
Head Office
The Artcomplex Center of Tokyo #302, 12-9, Daikyo-cho, Shinjuku-ku, Tokyo 160-0015, JAPAN
Contact
contact@heartseed.jp